BioNTech SE (22UA) — Cash Flow Reinvestment Rate
BioNTech SE (22UA) has a Cash Flow Reinvestment Rate of 9.66x as of December 2025, reinvesting €2.99 Billion (capex €62.10 Million plus investments €-2.93 Billion) from operating cash flow of €309.50 Million. Explore BioNTech SE capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNTech SE Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for BioNTech SE across 5 annual periods. Also explore BioNTech SE balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for BioNTech SE (2021–2025)
Year-by-year capital reinvestment analysis for BioNTech SE. For live market cap and broader valuation context, see BioNTech SE market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 5.83x | €2.66 Billion | €456.00 Million | €749.00 Million | ▼ -41.8% |
| 2024 | 10.03x | €2.08 Billion | €207.70 Million | €452.30 Million | ▲ +713.8% |
| 2023 | 1.23x | €6.62 Billion | €5.37 Billion | €705.50 Million | ▲ +4096.5% |
| 2022 | 0.03x | €398.60 Million | €13.58 Billion | €363.30 Million | ▼ -95.0% |
| 2021 | 0.59x | €522.20 Million | €889.70 Million | €127.50 Million | — |